MCID: MLG056
MIFTS: 62

Malignant Hyperthermia malady

Rare diseases, Neuronal diseases categories

Aliases & Classifications for Malignant Hyperthermia

About this section
Sources:
9Disease Ontology, 41NIH Rare Diseases, 21Genetics Home Reference, 11DISEASES, 47Orphanet, 60UMLS, 22GTR, 27ICD9CM, 38NCIt, 55SNOMED-CT, 33MeSH, 34MESH via Orphanet, 26ICD10 via Orphanet, 61UMLS via Orphanet, 25ICD10
See all sources

Malignant Hyperthermia, Aliases & Descriptions:

Name: Malignant Hyperthermia 9 41 21 11 47
Anesthesia Related Hyperthermia 9 41 21
Malignant Hyperpyrexia 41 21 47
Malignant Hyperpyrexia Due to Anesthesia 9 60
Hyperthermia, Malignant 21 22
Pharmacogenetic Myopathy of Anesthesia 47
Mhs - Malignant Hyperthermia 21
 
Hyperthermia of Anesthesia 47
Fulminating Hyperpyrexia 41
Hyperpyrexia, Malignant 21
Hyperpyrexia Malignant 41
Pharmacogenic Myopathy 41
Malignant Fever 60
Mh 41


Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Rare diseases
Anatomical: Neuronal diseases


Characteristics (Orphanet epidemiological data):

47
malignant hyperthermia:
Inheritance: Autosomal dominant; Age of onset: All ages; Age of death: normal life expectancy


External Ids:

Disease Ontology9 DOID:8545
ICD9CM27 995.86
NCIt38 C84869
MeSH33 D008305
Orphanet47 423
MESH via Orphanet34 D008305
ICD10 via Orphanet26 T88.3
UMLS via Orphanet61 C0024591

Summaries for Malignant Hyperthermia

About this section


NIH Rare Diseases:41 Malignant hyperthermia (mh) is a severe reaction to certain gases used during anesthesia and/or a muscle relaxant used to temporarily paralyze a person during surgery. signs and symptoms of mh include marked hyperthermia, a rapid heart rate, rapid breathing, acidosis, muscle rigidity, and breakdown of muscle tissue (rhabdomyolysis). without prompt treatment, mh can be life-threatening. people who are at increased risk for this reaction are said to have mh susceptibility. susceptibility to mh may be caused by mutations in any of several genes and is inherited in an autosomal dominant manner. people with certain inherited muscle diseases (e.g., central core disease and multiminicore disease) also have mh susceptibility. last updated: 6/30/2014

MalaCards based summary: Malignant Hyperthermia, also known as anesthesia related hyperthermia, is related to malignant hyperthermia susceptibility and central core disease. An important gene associated with Malignant Hyperthermia is RYR1 (ryanodine receptor 1 (skeletal)), and among its related pathways are Cardiac muscle contraction and Fc-GammaR Pathway. The drugs dantrolene and dantrolene sodium and the compounds nisoldipine and isradipine have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, testes and heart, and related mouse phenotypes are other and cardiovascular system.

Disease Ontology:9 A genetic disease that is characterized by a drastic and uncontrolled increase in skeletal muscle oxidative metabolism, which overwhelms the body's capacity to supply oxygen, remove carbon dioxide, and regulate body temperature.

Genetics Home Reference:21 Malignant hyperthermia is a severe reaction to particular drugs that are often used during surgery and other invasive procedures. Specifically, this reaction occurs in response to some anesthetic gases, which are used to block the sensation of pain, and with a muscle relaxant that is used to temporarily paralyze a person during a surgical procedure. If given these drugs, people at risk for malignant hyperthermia may experience muscle rigidity, breakdown of muscle fibers (rhabdomyolysis), a high fever, increased acid levels in the blood and other tissues (acidosis), and a rapid heart rate. Without prompt treatment, the complications of malignant hyperthermia can be life-threatening.

Wikipedia:63 Malignant hyperthermia (MH) or malignant hyperpyrexia is a rare life-threatening condition that is... more...

Related Diseases for Malignant Hyperthermia

About this section

Diseases related to Malignant Hyperthermia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 100)
idRelated DiseaseScoreTop Affiliating Genes
1malignant hyperthermia susceptibility32.3RYR1, CACNA1S
2central core disease31.6CACNA1S, RYR1
3myopathy31.0SCN4A, CPT2, CACNA1S, RYR1
4neuromuscular disease30.5SCN4A, RYR1
5malignant hyperthermia susceptibility 110.6
6malignant hyperthermia susceptibility 510.5
7malignant hyperthermia arthrogryposis torticollis10.5
8native american myopathy10.4
9neuroleptic malignant syndrome10.4
10muscular dystrophy10.4
11malignant hyperthermia susceptibility type 210.4
12malignant hyperthermia susceptibility type 310.4
13malignant hyperthermia susceptibility type 410.4
14malignant hyperthermia susceptibility type 610.4
15myotonia10.4
16schwartz-jampel syndrome, type 110.3
17multiple pterygium syndrome, lethal type10.3
18larsen syndrome10.3
19wolf-hirschhorn syndrome10.3
20becker muscular dystrophy10.3
21ryr1-related malignant hyperthermia susceptibility10.3
22mhs2-related malignant hyperthermia susceptibility10.3
23mhs3-related malignant hyperthermia susceptibility10.3
24mhs4-related malignant hyperthermia susceptibility10.3
25cacna1s-related malignant hyperthermia susceptibility10.3
26mhs6-related malignant hyperthermia susceptibility10.3
27hypokalemia10.2CACNA1S, SCN4A
28ectodermal dysplasia 10a, hypohidrotic/hair/nail type, autosomal dominant10.2
29smith-lemli-opitz syndrome10.2
30moebius syndrome10.2
31ichthyosis, autosomal recessive 4b10.2
32dysautonomia, familial10.2
33glutaricaciduria, type i10.2
34yellow fever10.2
35distal arthrogryposis10.2
36cold-induced sweating syndrome10.2
37compartment syndrome10.2
38congenital contractures10.2
39brain disease10.2RYR1, CPT2
40malignant histiocytosis10.2
41histiocytosis10.2
42hypokalemic periodic paralysis, type 110.2SCN4A, CACNA1S, RYR1
43dilated cardiomyopathy10.1RYR1, CALR, CPT2
44schizophrenia10.0
45myoglobinuria, acute recurrent, autosomal recessive10.0
46rippling muscle disease10.0
47holt-oram syndrome10.0
48brody myopathy10.0
49arthrogryposis, distal, type 2a10.0
50campomelic dysplasia10.0

Graphical network of the top 20 diseases related to Malignant Hyperthermia:



Diseases related to malignant hyperthermia

Symptoms for Malignant Hyperthermia

About this section

Drugs & Therapeutics for Malignant Hyperthermia

About this section

Drug clinical trials:

Search ClinicalTrials for Malignant Hyperthermia

Search NIH Clinical Center for Malignant Hyperthermia

Inferred drug relations via UMLS60/NDF-RT39:

Genetic Tests for Malignant Hyperthermia

About this section

Genetic tests related to Malignant Hyperthermia:

id Genetic test Affiliating Genes
1 Malignant Hyperthermia22

Anatomical Context for Malignant Hyperthermia

About this section

MalaCards organs/tissues related to Malignant Hyperthermia:

31
Skeletal muscle, Testes, Heart, Liver, Brain, Cerebellum, Kidney, Thyroid, Placenta, B cells

Animal Models for Malignant Hyperthermia or affiliated genes

About this section

MGI Mouse Phenotypes related to Malignant Hyperthermia:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053959.0CAV1, NME1, RYR1
2MP:00053858.1RYR1, CAV1, CACNA2D1, CALR, ASPH
3MP:00053818.0ASPH, HTR2A, CACNA1S, CAV1, RYR1
4MP:00053788.0SCN4A, CACNA1S, CALR, CAV1, NME1, RYR1
5MP:00107687.6SCN4A, ASPH, CACNA1S, CALR, CAV1, NME1
6MP:00053867.6SCN4A, HTR2A, CACNA1S, CACNA2D1, CAV1, RYR1
7MP:00053767.5ASPH, CACNA1S, CALR, CAV1, NME1, RYR1
8MP:00053696.7RYR1, SCN4A, ASPH, HTR2A, CACNA1S, CALR

Publications for Malignant Hyperthermia

About this section

Articles related to Malignant Hyperthermia:

(show top 50)    (show all 696)
idTitleAuthorsYear
1
Contractile elements in muscular fascial tissue - implications for in-vitro contracture testing for malignant hyperthermia. (24909539)
2014
2
Manufacturer's response to Bilmen and Gillies' manuscript entitled "Clarifying the role of activated charcoal filters in preparing an anaesthetic workstation for malignant hyperthermia-susceptible patients". (25342416)
2014
3
Editorial comment: improving awareness of nonanesthesia-related malignant hyperthermia presentations: a tale of two brothers. (25611020)
2014
4
Additional evidence that the ryanodine receptor gene (RYR1) causes malignant hyperthermia and severe skeletal malformations. (23239586)
2013
5
Malignant Hyperthermia-Like Manifestations in a Two-Month-Old Child with Holt-Oram Syndrome Undergoing Cardiac Surgery. (24011877)
2013
6
Altered Ca2+ concentration, permeability and buffering in the myofibre Ca2+ store of a mouse model of malignant hyperthermia. (23798496)
2013
7
Case report: clearance to dive for a naval candidate with family history of malignant hyperthermia. (23957207)
2013
8
Sudden death due to malignant hyperthermia during general anesthesia. (23879013)
2013
9
Malignant hyperthermia in endosulfan poisoning. (22736908)
2012
10
Nonanesthetic malignant hyperthermia. (21878807)
2011
11
Malignant hyperthermia in the oral and maxillofacial surgery patient: an update. (21827956)
2011
12
Excess comorbidities associated with malignant hyperthermia diagnosis in pediatric hospital discharge records. (21722230)
2011
13
Prevalence of malignant hyperthermia and relationship with anesthetics in Japan: data from the diagnosis procedure combination database. (21169796)
2011
14
New device simplifies workstation preparation for malignant hyperthermia-susceptible patients. (21791993)
2011
15
Minimally invasive metabolic testing for malignant hyperthermia susceptibility: a systematic review of the methodology and results. (23484448)
2010
16
Intramuscular injection of malignant hyperthermia trigger agents induces hypermetabolism in susceptible and nonsusceptible individuals. (19809329)
2010
17
Characterization and temporal development of cores in a mouse model of malignant hyperthermia. (19966218)
2009
18
Preparation of the DrAoger Fabius GS workstation for malignant hyperthermia-susceptible patients. (19399571)
2009
19
Novel ryanodine receptor mutation that may cause malignant hyperthermia. (18719443)
2008
20
Recurrent postoperative deep vein thrombosis in a patient with obstructive sleep apnea and malignant hyperthermia susceptibility. (18056220)
2007
21
An assessment of a point-of-care information system for the anesthesia provider in simulated malignant hyperthermia crisis. (16428555)
2006
22
Gene symbol: RYR1. Disease: malignant hyperthermia. (16521286)
2005
23
Cumulative and bolus in vitro contracture testing with 4-chloro-3-ethylphenol in malignant hyperthermia positive and negative human skeletal muscles. (16115979)
2005
24
Desflurane, malignant hyperthermia, and release of compartment syndrome. (15845684)
2005
25
Sewing hot and cold: successful replant of a hand in a patient who developed malignant hyperthermia intraoperatively. (15629174)
2005
26
Central hyperthermia suspected of malignant hyperthermia in a patient undergoing radical neck clipping for cerebral aneurysm]. (15717469)
2005
27
Malignant hyperthermia with excellent response to small dose of dantrolene. (15679136)
2004
28
Malignant hyperthermia. (14764260)
2004
29
Sevoflurane-induced malignant hyperthermia during cardiopulmonary bypass and moderate hypothermia. (15315628)
2004
30
Malignant hyperthermia and the otolaryngologist. (12861868)
2003
31
Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript. (12883402)
2003
32
Novel mutations in C-terminal channel region of the ryanodine receptor in malignant hyperthermia patients. (11928716)
2002
33
Positive malignant hyperthermia susceptibility in vitro test in a patient with mitochondrial myopathy and myoadenylate deaminase deficiency. (12459698)
2002
34
Malignant hyperthermia: how to spot it early. (12136527)
2002
35
Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation. (12220451)
2002
36
Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. (12411788)
2002
37
Fatal malignant hyperthermia--delayed onset and atypical course. (12372688)
2002
38
Heat production during anesthetic-induced malignant hyperthermia. (11725865)
2001
39
Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). (11575546)
2001
40
Malignant hyperthermia. (11268159)
2001
41
Differential diagnosis of thyroid crisis and malignant hyperthermia in an anesthetized porcine model. (10098596)
1999
42
Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors. (9502764)
1998
43
Sodium channel in human malignant hyperthermia. (9158350)
1997
44
Malignant hyperthermia suggestive hypermetabolic syndrome at emergence from anesthesia. (8714856)
1995
45
Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. (8012359)
1994
46
Alteration of intracellular Ca2+ transients in COS-7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia. (8053891)
1994
47
Spin resonance spectroscopy to detect malignant hyperthermia susceptibility. (8391293)
1993
48
Malignant Hyperthermia Susceptibility (20301325)
1993
49
Does postoperative pyrexia indicate malignant hyperthermia susceptibility? (1540466)
1992
50
Porcine malignant hyperthermia susceptibility: increased calcium-sequestering activity of skeletal muscle sarcoplasmic reticulum. (3742368)
1986

Variations for Malignant Hyperthermia

About this section

Clinvar genetic disease variations for Malignant Hyperthermia:

6 (show all 20)
id Gene Variation Type Significance SNP ID Assembly Location
1RYR1NM_000540.2(RYR1): c.1840C> T (p.Arg614Cys)single nucleotide variantrisk factorrs118192172GRCh37Chr 19, 38948185: 38948185
2RYR1NM_000540.2(RYR1): c.742G> A (p.Gly248Arg)single nucleotide variantrisk factorrs1801086GRCh37Chr 19, 38937350: 38937350
3RYR1NM_000540.2(RYR1): c.487C> T (p.Arg163Cys)single nucleotide variantPathogenic, risk factorrs118192161GRCh37Chr 19, 38934851: 38934851
4RYR1NM_000540.2(RYR1): c.1021G> A (p.Gly341Arg)single nucleotide variantrisk factorrs121918592GRCh37Chr 19, 38939352: 38939352
5RYR1NM_000540.2(RYR1): c.7300G> A (p.Gly2434Arg)single nucleotide variantrisk factorrs121918593GRCh37Chr 19, 38990633: 38990633
6RYR1NM_000540.2(RYR1): c.7372C> T (p.Arg2458Cys)single nucleotide variantrisk factorrs28933397GRCh37Chr 19, 38991294: 38991294
7RYR1NM_000540.2(RYR1): c.7373G> A (p.Arg2458His)single nucleotide variantPathogenic, risk factorrs121918594GRCh37Chr 19, 38991295: 38991295
8RYR1NM_000540.2(RYR1): c.6487C> T (p.Arg2163Cys)single nucleotide variantPathogenic, risk factorrs118192175GRCh37Chr 19, 38985204: 38985204
9RYR1NM_000540.2(RYR1): c.6488G> A (p.Arg2163His)single nucleotide variantPathogenic, risk factorrs118192163GRCh37Chr 19, 38985205: 38985205
10RYR1NM_000540.2(RYR1): c.14693T> C (p.Ile4898Thr)single nucleotide variantPathogenic, risk factorrs118192170GRCh37Chr 19, 39075629: 39075629
11RYR1NM_000540.2(RYR1): c.6502G> A (p.Val2168Met)single nucleotide variantrisk factorrs118192176GRCh37Chr 19, 38985219: 38985219
12RYR1NM_000540.2(RYR1): c.6617C> T (p.Thr2206Met)single nucleotide variantrisk factorrs118192177GRCh37Chr 19, 38986923: 38986923
13RYR1NM_000540.2(RYR1): c.14477C> T (p.Thr4826Ile)single nucleotide variantrisk factorrs121918595GRCh37Chr 19, 39070734: 39070734
14RYR1NM_000540.2(RYR1): c.14387A> G (p.Tyr4796Cys)single nucleotide variantPathogenic, risk factorrs118192167GRCh37Chr 19, 39070644: 39070644
15RYR1NM_000540.2(RYR1): c.7039_7041delGAG (p.Glu2348del)deletionrisk factorrs121918596GRCh37Chr 19, 38990286: 38990288
16RYR1NM_000540.2(RYR1): c.8026C> T (p.Arg2676Trp)single nucleotide variantrisk factorrs193922826GRCh37Chr 19, 38994959: 38994959
17RYR1NM_000540.2(RYR1): c.1565A> C (p.Tyr522Ser)single nucleotide variantPathogenic, risk factorrs118192162GRCh37Chr 19, 38945999: 38945999
18RYR1NM_000540.2(RYR1): c.8026C> T (p.Arg2676Trp)single nucleotide variantrisk factorrs193922826GRCh37Chr 19, 38994959: 38994959
19RYR1NM_000540.2(RYR1): c.8360C> G (p.Thr2787Ser)single nucleotide variantrisk factorrs35180584GRCh37Chr 19, 38995998: 38995998
20CACNA1SNM_000069.2(CACNA1S): c.3257G> A (p.Arg1086His)single nucleotide variantrisk factorrs1800559GRCh37Chr 1, 201029943: 201029943

Expression for genes affiliated with Malignant Hyperthermia

About this section
Search GEO for disease gene expression data for Malignant Hyperthermia.

Pathways for genes affiliated with Malignant Hyperthermia

About this section

Pathways related to Malignant Hyperthermia according to GeneCards Suite gene sharing:

(show all 15)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.6CACNA2D1, CACNA1S
2
Show member pathways
9.6CACNA2D1, CACNA1S
39.6CACNA1S, CACNA2D1
4
Show member pathways
Calcium Regulation in the Cardiac Cell36
9.4CACNA1S, CALR, RYR1
5
Show member pathways
9.3RYR1, CACNA2D1, CACNA1S
6
Show member pathways
9.3CACNA1S, CACNA2D1, RYR1
79.3CACNA1S, CACNA2D1, RYR1
8
Show member pathways
9.2CACNA1S, CALR, CACNA2D1
9
Show member pathways
9.0RYR1, CACNA1S, HTR2A
109.0RYR1, CACNA1S, HTR2A
11
Show member pathways
Development Ligand independent activation of ESR1 and ESR258
9.0CAV1, CACNA2D1, CACNA1S
12
Show member pathways
9.0SCN4A, CACNA1S, CACNA2D1, RYR1
138.9RYR1, CACNA2D1, CALR, CACNA1S
14
Show member pathways
8.6CAV1, CACNA2D1, CACNA1S, SCN4A
15
Show member pathways
8.5HTR2A, CACNA1S, CACNA2D1, RYR1

Compounds for genes affiliated with Malignant Hyperthermia

About this section

Compounds related to Malignant Hyperthermia according to GeneCards Suite gene sharing:

(show all 36)
idCompoundScoreTop Affiliating Genes
1nisoldipine28 43 1212.0CACNA2D1, CACNA1S
2isradipine43 28 1212.0CACNA2D1, CACNA1S
3nilvadipine43 1211.0CACNA2D1, CACNA1S
4nitrendipine43 49 28 1212.9CACNA2D1, CACNA1S
5felodipine43 28 1211.9CACNA1S, CACNA2D1
6amlodipine43 49 24 1212.9CACNA2D1, CACNA1S
7succinylcholine43 49 28 1212.9RYR1, CACNA1S, SCN4A
8halothane43 49 28 1212.8CALR, RYR1
9ouabain43 1210.8RYR1, CAV1
10nifedipine43 28 49 1212.7CACNA1S, CACNA2D1, RYR1
11glyceraldehyde 3-phosphate439.6RYR1, NME1, CALR
12pyruvate439.6CPT2, CALR, NME1
13inositol 1,4,5 trisphosphate439.4CALR, CAV1, RYR1
14thapsigargin43 5910.4RYR1, CAV1, CALR
15glutamine439.3RYR1, NME1, CALR
16histidine439.3SCN4A, CACNA1S, CALR, NME1
17ryanodine43 28 5911.3ASPH, CACNA1S, CALR, RYR1
18hydrogen43 2410.1RYR1, CAV1, CALR, CPT2
19chloride439.1RYR1, CAV1, CALR, SCN4A
20sodium43 2410.1CAV1, CALR, CACNA1S, SCN4A
21gtp43 2810.1NME1, CAV1, CALR
22glutamate439.0CPT2, CALR, CAV1, RYR1
23fatty acid439.0CPT2, CALR, CAV1, NME1
24nitric oxide43 24 1211.0RYR1, NME1, CAV1, CALR
25lactate439.0NME1, CALR, CPT2
26glucose438.9CPT2, CALR, CAV1, RYR1
27dihydropyridine438.9RYR1, CALR, CACNA1S, ASPH, SCN4A
28cysteine438.9CALR, CAV1, NME1, RYR1
29oxygen43 249.8ASPH, CALR, CAV1, RYR1
30arginine438.8SCN4A, CACNA1S, CALR, CAV1, RYR1
31iron43 249.8ASPH, CALR, CAV1
32lipid438.8RYR1, CAV1, CALR, CPT2
33phosphoinositide438.7CAV1, CALR, HTR2A
34serine438.6CPT2, CALR, CAV1, NME1, RYR1
35atp43 289.4SCN4A, CPT2, CALR, CAV1, NME1, RYR1
36calcium43 49 24 129.5SCN4A, ASPH, HTR2A, CACNA1S, CALR, CACNA2D1

GO Terms for genes affiliated with Malignant Hyperthermia

About this section

Cellular components related to Malignant Hyperthermia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1I bandGO:00316749.9CACNA1S, RYR1
2junctional sarcoplasmic reticulum membraneGO:00147019.8RYR1, ASPH
3sarcoplasmic reticulum lumenGO:00330189.6CALR, ASPH
4voltage-gated calcium channel complexGO:00058919.6CACNA2D1, CACNA1S
5sarcoplasmic reticulum membraneGO:00330179.6RYR1, ASPH
6sarcoplasmic reticulumGO:00165299.5RYR1, CACNA2D1, CACNA1S
7T-tubuleGO:00303159.5CACNA1S, CACNA2D1, RYR1
8caveolaGO:00059019.0CAV1, HTR2A
9integral component of plasma membraneGO:00058878.1SCN4A, HTR2A, CAV1, RYR1

Biological processes related to Malignant Hyperthermia according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1skeletal muscle fiber developmentGO:004874110.0RYR1, CACNA1S
2cytosolic calcium ion homeostasisGO:00514809.6RYR1, CAV1
3response to testosteroneGO:00335749.5NME1, CALR
4positive regulation of calcium ion transport into cytosolGO:00105249.5ASPH, CAV1
5lactationGO:00075959.4NME1, CAV1
6muscle contractionGO:00069369.2SCN4A, ASPH, CACNA1S, RYR1
7release of sequestered calcium ion into cytosolGO:00512099.1RYR1, HTR2A
8positive regulation of vasoconstrictionGO:00459079.0HTR2A, CAV1
9calcium ion transportGO:00068168.9RYR1, CAV1, CACNA2D1, CACNA1S
10cellular calcium ion homeostasisGO:00068748.8CAV1, CALR, HTR2A

Molecular functions related to Malignant Hyperthermia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1voltage-gated calcium channel activityGO:00052459.3RYR1, CACNA2D1, CACNA1S

Products for genes affiliated with Malignant Hyperthermia

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Malignant Hyperthermia

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCIt
39NDF-RT
42NINDS
43Novoseek
45OMIM
46OMIM via Orphanet
50PubMed
51QIAGEN
56SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet